Country Lead, Flow Neuroscience

Flow's device delivers a gentle electrical current to the part of the brain that regulates mood, offering a non-drug alternative that patients can use outside of a clinical setting under remote supervision. The treatment has already been used by more than 55,000 people across Hong Kong, the UK, Switzerland and other parts of Europe. Clinical research has produced promising results, including studies showing that a significant proportion of patients experience symptom improvement within weeks of starting treatment.

In a major milestone for the company, the US Food and Drug Administration approved Flow's FL-100 headset to treat moderate to severe major depressive disorder in adults. This approval makes it the first at-home brain stimulation device cleared for depression treatment in the US. With this, the company plans to launch the device in the US later in 2026 as a prescription treatment, expanding its reach and bringing its technology to a much larger patient population.